<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287376</url>
  </required_header>
  <id_info>
    <org_study_id>81-0076</org_study_id>
    <nct_id>NCT02287376</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics &amp; Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds</brief_title>
  <official_title>A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia® (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Depomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Depomed</source>
  <brief_summary>
    <textblock>
      Study Objectives:

        1. The primary objective is to characterize the pharmacokinetics of a single oral
           administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis
           of episodic migraine with or without aura.

        2. The secondary objectives are to determine:

             1. The safety and tolerability of Cambia from a single dose

             2. Three-month safety evaluation of Cambia in outpatient usage in this population
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Outcome (1 of 6)</measure>
    <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
    <description>• Cmax: maximum concentration (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Outcome (2 of 6)</measure>
    <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
    <description>• tmax: time to maximum concentration (min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Outcome (3 of 6)</measure>
    <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
    <description>• λz: elimination rate constant associated with the terminal (log linear) portion of the curve (1/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Outcome (4 of 6)</measure>
    <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
    <description>• t1/2: terminal elimination half-life (min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Outcome (5 of 6)</measure>
    <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
    <description>• AUC 0-t: area under the concentration-time curve from time 0 to last time point (t) where diclofenac could be measured (min*ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Outcome (6 of 6)</measure>
    <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
    <description>• AUC 0-∞: area under the concentration-time curve from time 0 to infinity (∞) (min*ng/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (1 of 7)</measure>
    <time_frame>3 months (time of first dose of study medication taken to 30 days after the last dose of study medication taken)</time_frame>
    <description>• Treatment emergent AEs (TEAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (2 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to 30 days post Day 90 or last dose of study medication taken)</time_frame>
    <description>• Serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (3 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to 30 days after the last dose of study medication taken)</time_frame>
    <description>• Withdrawals due to AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (4 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to 30 days post Day 90 or last dose of study medication taken)</time_frame>
    <description>• Deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (5.1 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in vital sign measurements: Temperature (degrees C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (5.2 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in vital sign measurements: Heart Rate (beats/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (5.3 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in vital sign measurements: Respiratory Rate (breaths/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (5.4 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in vital sign measurements: Systolic Blood Pressure (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (5.5 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in vital sign measurements: Diastolic Blood Pressure (mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.1 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Hematocrit (L/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.2 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Hemoglobin (g/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.3 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Platelet Count (Cells * 10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.4 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - White Blood Cells (Cells * 10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.5 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Basophils (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.6 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Eosinophils (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.7 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Neutrophils (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.8 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Lymphocytes (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.9 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Hematology - Monocytes (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.10 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Albumin (g/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.11 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Alkaline Phosphatase (U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.12 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - ALT (SGPT) (U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.13 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - AST (SGOT) (U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.14 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Bicarbonate (CO2) (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.15 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Bilirubin Total (umol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.16 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - BUN (Urea) (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.17 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Chloride (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.18 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Creatinine (umol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.19 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Glucose (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.20 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - LDH (U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.21 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Potassium (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.22 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Chemistry - Sodium (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.23 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Urinalysis - pH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (6.24 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Changes in clinical laboratory results: Urinalysis - Specific Gravity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome (7 of 7)</measure>
    <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
    <description>• Physical examination findings including abnormal clinically significant findings</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Diclofenac Potassium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Potassium for Oral Solution 50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Potassium for Oral Solution</intervention_name>
    <description>NSAID</description>
    <arm_group_label>Diclofenac Potassium</arm_group_label>
    <other_name>Cambia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥12 and ≤17 years of age at screening.

          2. Subject diagnosed with episodic migraine with or without aura for at least 3 months
             (migraine defined based on the International classification of headache disorders-II
             1.2.1 or 1.1).

          3. Subject has 14 or fewer headache days per month.

          4. Subject receiving prophylactic treatment for migraine may be included.

          5. If female, is not of childbearing potential (defined as premenarchal) or if of
             childbearing potential must have a negative serum pregnancy test at screening and a
             negative urine pregnancy test on Study Day 1, if the Screening visit and Day 1 are not
             on the same day, and must use medically acceptable methods of birth control as listed
             below and agrees to continue its use throughout the study:1) hormonal methods (e.g.,
             oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full
             menstrual cycle before study drug administration), 2) Total abstinence from sexual
             intercourse since the last menses before study drug administration, 3) intrauterine
             device, 4) double-barrier method (e.g., condoms, sponge, diaphragm, or vaginal ring
             with spermicidal jellies or cream).

          6. Subject's legally authorized representative (e.g., parent, guardian) must voluntarily
             sign and date an informed consent form (ICF) that is approved by an Institutional
             Review Board (IRB), and the subject must sign an assent (if appropriate), before the
             commencement of any study assessment.

          7. Subject's legally authorized representative (e.g., parent, guardian) and subject (if
             appropriate), is able to read and understand the study procedures and requirements and
             adhere to the protocol requirements and procedures.

        Exclusion Criteria:

          1. Subject has a known history of allergic reaction, hypersensitivity, or clinically
             significant intolerance to diclofenac, aspirin, or any nonsteroidal anti inflammatory
             drugs (NSAIDs); history of NSAID induced bronchospasm (subjects with the triad of
             asthma, nasal polyps, and chronic rhinitis are at greater risk for bronchospasm and
             should be considered carefully); or hypersensitivity, allergy, or significant reaction
             to the non-active ingredients of the study medication.

          2. Subject is pregnant or lactating or considered at risk of pregnancy.

          3. Subject has been under an inconsistent dosing regimen of prophylactic treatment for
             migraine.

          4. Subject has headache symptoms likely due to, or aggravated by, traumatic injury to the
             head or neck region, such as whiplash, within the last six months;

          5. Subject has or is suspected of having a secondary headache.

          6. Subject has significant abnormal findings during the neurological exam at screening.

          7. Subject has a history of any GI event (e.g., perforation, obstruction, bleed) before
             Screening that, in the opinion of the investigator, would make the subject unsuitable
             for study participation.

          8. Subject is receiving any medication that, in the opinion of the investigator, may
             cause a clinically significant condition when used concomitantly with diclofenac
             (e.g., aspirin, anticoagulants, ACE inhibitors, methotrexate, cyclosporine,
             furosemide, lithium).

          9. Subject is and has been receiving a medication that is known to strongly inhibit
             and/or induce cytochrome P450 2C9 such that it might unpredictably affect the
             pharmacokinetics of diclofenac (e.g., fluconazole, amiodarone, oxandrolone,
             sulfipyrazone as inhibitors and rifampin as an inducer).

         10. Subject has any condition or any laboratory abnormality that would, in the opinion of
             the investigator, contraindicate study participation.

         11. Subject has impaired liver function (e.g., alanine aminotransferase [ALT] ≥ 3 times
             the upper limit of normal [ULN] or bilirubin ≥ 3 times ULN), known active hepatic
             disease (e.g., hepatitis), or evidence of clinically significant liver disease or
             other condition affecting the liver that may suggest the potential for an increased
             susceptibility to hepatic toxicity with oral diclofenac exposure.

         12. Subject has any history of renal disease that, in the opinion of the investigator,
             would contraindicate study participation; or subject has significantly impaired renal
             function as evidenced by an estimated GFR of ≤60 ml/min/1.73m2.

         13. Subject is considered by the investigator, for any reason (including, but not limited
             to the risks described as precautions, warnings, and contraindications in the
             Prescribing Information for Cambia), to be an unsuitable candidate to receive the
             study medication.

         14. Subject has a history of laboratory test results obtained within 6 months before the
             Screening visit that show the presence of HIV, hepatitis B surface antigen, hepatitis
             C antibody, or active hepatitis A immunoglobulin M.

         15. Subject is currently receiving any medication that is contraindicated for use
             concomitantly with diclofenac (refer to the products' professional labeling) or the
             subject has not undergone a washout period of at least 5-6 half-lives of PK or PD,
             whichever is longer, for these medications.

         16. Subject has a known or suspected history of alcohol use and or drug/ substance abuse
             or misuse within 2 years before Screening; or evidence of tolerance or physical
             dependence before study medication administration.

         17. Subject has a documented history of a medical condition that, in the opinion of the
             investigator, would compromise the subject's ability to absorb, metabolize, or excrete
             diclofenac, including (but not limited to) intractable nausea and/or vomiting and/or
             severe GI narrowing (pathologic or iatrogenic).

         18. Subject has received any investigational product or device within 30 days before the
             Screening, or is scheduled to receive an investigational device or another
             investigational drug (other than Cambia) during the course of this study.

         19. Subject is a relative of a member of the study site staff or Sponsor directly involved
             in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <results_first_submitted>January 24, 2017</results_first_submitted>
  <results_first_submitted_qc>July 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 25, 2017</results_first_posted>
  <last_update_submitted>July 22, 2017</last_update_submitted>
  <last_update_submitted_qc>July 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine with and without aura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cambia®</title>
          <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cambia®</title>
          <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.5" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics Outcome (1 of 6)</title>
        <description>• Cmax: maximum concentration (ng/mL)</description>
        <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
        <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Outcome (1 of 6)</title>
          <description>• Cmax: maximum concentration (ng/mL)</description>
          <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1411.96" spread="846.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="649.78" spread="1008.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1123.88" spread="881.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1247.72" spread="824.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1084.52" spread="575.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="855.92" spread="469.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="629.96" spread="295.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 min post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="535.44" spread="295.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.25" spread="107.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hrs post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.20" spread="25.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hrs post-dose concentrations (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.26" spread="7.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics Outcome (2 of 6)</title>
        <description>• tmax: time to maximum concentration (min)</description>
        <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
        <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Outcome (2 of 6)</title>
          <description>• tmax: time to maximum concentration (min)</description>
          <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" spread="11.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics Outcome (3 of 6)</title>
        <description>• λz: elimination rate constant associated with the terminal (log linear) portion of the curve (1/min)</description>
        <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
        <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Outcome (3 of 6)</title>
          <description>• λz: elimination rate constant associated with the terminal (log linear) portion of the curve (1/min)</description>
          <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
          <units>1/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics Outcome (4 of 6)</title>
        <description>• t1/2: terminal elimination half-life (min)</description>
        <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
        <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Outcome (4 of 6)</title>
          <description>• t1/2: terminal elimination half-life (min)</description>
          <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.79" spread="9.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics Outcome (5 of 6)</title>
        <description>• AUC 0-t: area under the concentration-time curve from time 0 to last time point (t) where diclofenac could be measured (min*ng/mL)</description>
        <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
        <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Outcome (5 of 6)</title>
          <description>• AUC 0-t: area under the concentration-time curve from time 0 to last time point (t) where diclofenac could be measured (min*ng/mL)</description>
          <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
          <units>min*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82920.03" spread="25327.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics Outcome (6 of 6)</title>
        <description>• AUC 0-∞: area under the concentration-time curve from time 0 to infinity (∞) (min*ng/mL)</description>
        <time_frame>6 hours (pre-dose, 5, 10, 15, 20, 30, 40, and 60 min, and 2, 4, and 6 hrs post-dose)</time_frame>
        <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Outcome (6 of 6)</title>
          <description>• AUC 0-∞: area under the concentration-time curve from time 0 to infinity (∞) (min*ng/mL)</description>
          <population>The PK population included all subjects in the Safety population who have at least 1 time point with quantifiable study drug concentration after dosing.</population>
          <units>min*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84388.75" spread="25993.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (1 of 7)</title>
        <description>• Treatment emergent AEs (TEAEs)</description>
        <time_frame>3 months (time of first dose of study medication taken to 30 days after the last dose of study medication taken)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (1 of 7)</title>
          <description>• Treatment emergent AEs (TEAEs)</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (2 of 7)</title>
        <description>• Serious adverse events (SAEs)</description>
        <time_frame>3 months (signed informed consent/assent to 30 days post Day 90 or last dose of study medication taken)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (2 of 7)</title>
          <description>• Serious adverse events (SAEs)</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (3 of 7)</title>
        <description>• Withdrawals due to AEs</description>
        <time_frame>3 months (signed informed consent/assent to 30 days after the last dose of study medication taken)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (3 of 7)</title>
          <description>• Withdrawals due to AEs</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (4 of 7)</title>
        <description>• Deaths</description>
        <time_frame>3 months (signed informed consent/assent to 30 days post Day 90 or last dose of study medication taken)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (4 of 7)</title>
          <description>• Deaths</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (5.1 of 7)</title>
        <description>• Changes in vital sign measurements: Temperature (degrees C).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (5.1 of 7)</title>
          <description>• Changes in vital sign measurements: Temperature (degrees C).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>degrees C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (degrees C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.52" spread="0.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (degrees C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.72" spread="0.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (degrees C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (5.2 of 7)</title>
        <description>• Changes in vital sign measurements: Heart Rate (beats/min).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (5.2 of 7)</title>
          <description>• Changes in vital sign measurements: Heart Rate (beats/min).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (beats/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (beats/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (beats/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (5.3 of 7)</title>
        <description>• Changes in vital sign measurements: Respiratory Rate (breaths/min).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (5.3 of 7)</title>
          <description>• Changes in vital sign measurements: Respiratory Rate (breaths/min).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (breaths/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (breaths/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (breaths/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (5.4 of 7)</title>
        <description>• Changes in vital sign measurements: Systolic Blood Pressure (mmHg).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (5.4 of 7)</title>
          <description>• Changes in vital sign measurements: Systolic Blood Pressure (mmHg).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mm Hg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.7" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mm Hg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.6" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mm Hg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (5.5 of 7)</title>
        <description>• Changes in vital sign measurements: Diastolic Blood Pressure (mmHg).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (5.5 of 7)</title>
          <description>• Changes in vital sign measurements: Diastolic Blood Pressure (mmHg).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mm Hg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mm Hg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mm Hg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.1 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Hematocrit (L/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.1 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Hematocrit (L/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>L/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (L/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.388" spread="0.0329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (L/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.408" spread="0.0344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (L/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.2 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Hemoglobin (g/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.2 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Hemoglobin (g/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.000" spread="11.4419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.720" spread="11.6638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.720" spread="5.4430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.3 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Platelet Count (Cells * 10^9/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.3 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Platelet Count (Cells * 10^9/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>Cells * 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Cells * 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.640" spread="43.4855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (Cells * 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.960" spread="47.0049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (Cells*10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.320" spread="42.3642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.4 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - White Blood Cells (Cells * 10^9/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.4 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - White Blood Cells (Cells * 10^9/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>Cells * 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Cells * 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.512" spread="1.9935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (Cells * 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.262" spread="1.4957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (Cells*10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.249" spread="2.0634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.5 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Basophils (%).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.5 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Basophils (%).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>% Basophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (% Basophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.324" spread="0.3829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (% Basophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.350" spread="0.3766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (% Basophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.5190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.6 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Eosinophils (%).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.6 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Eosinophils (%).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>% Eosinophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (% Eosinophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.730" spread="2.0728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (% Eosinophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.036" spread="1.6519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit(% Eosinophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.694" spread="1.7186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.7 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Neutrophils (%).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.7 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Neutrophils (%).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>% Neutrophils</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (% Neutrophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.530" spread="9.7221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (% Neutrophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.932" spread="8.4095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit(% Neutrophils)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.402" spread="10.1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.8 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Lymphocytes (%).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.8 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Lymphocytes (%).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>% Lymphocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (% Lymphocytes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.260" spread="8.9981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (% Lymphocytes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.745" spread="7.5260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit(% Lymphocytes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.515" spread="9.1165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.9 of 7)</title>
        <description>• Changes in clinical laboratory results: Hematology - Monocytes (%).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.9 of 7)</title>
          <description>• Changes in clinical laboratory results: Hematology - Monocytes (%).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>% Monocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (% Monocytes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.030" spread="1.8765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (% Monocytes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.847" spread="1.7170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (% Monocytes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.183" spread="1.7852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.10 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Albumin (g/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.10 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Albumin (g/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.800" spread="4.0415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.200" spread="4.4441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.400" spread="3.0277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.11 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Alkaline Phosphatase (U/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.11 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Alkaline Phosphatase (U/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.960" spread="85.0022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.760" spread="89.5378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.800" spread="11.4054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.12 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - ALT (SGPT) (U/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.12 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - ALT (SGPT) (U/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.680" spread="5.7134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.080" spread="5.1553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.400" spread="2.0817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.13 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - AST (SGOT) (U/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.13 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - AST (SGOT) (U/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.240" spread="4.5760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.040" spread="4.6947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" spread="2.6615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.14 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Bicarbonate (CO2) (mmol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.14 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Bicarbonate (CO2) (mmol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.400" spread="1.8028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.920" spread="2.1970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.520" spread="2.7099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.15 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Bilirubin Total (umol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.15 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Bilirubin Total (umol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (umol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.029" spread="4.1454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (umol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.192" spread="5.5311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (umol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.163" spread="3.9107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.16 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - BUN (Urea) (mmol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.16 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - BUN (Urea) (mmol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.512" spread="1.0858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.594" spread="1.2965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081" spread="1.0515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.17 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Chloride (mmol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.17 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Chloride (mmol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.480" spread="1.9604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.880" spread="2.7435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.600" spread="2.1602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.18 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Creatinine (umol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.18 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Creatinine (umol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (umol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.760" spread="11.2603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (umol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.467" spread="10.7228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (umol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.707" spread="8.1866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.19 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Glucose (mmol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.19 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Glucose (mmol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.758" spread="0.6037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.483" spread="0.8590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.275" spread="0.9215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.20 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - LDH (U/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.20 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - LDH (U/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.882" spread="59.0824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.708" spread="41.5425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.882" spread="74.6064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.21 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Potassium (mmol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.21 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Potassium (mmol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.964" spread="0.2215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.060" spread="0.2784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" spread="0.3007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.22 of 7)</title>
        <description>• Changes in clinical laboratory results: Chemistry - Sodium (mmol/L).</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.22 of 7)</title>
          <description>• Changes in clinical laboratory results: Chemistry - Sodium (mmol/L).</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.640" spread="1.0360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.840" spread="1.5188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.200" spread="1.6833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.23 of 7)</title>
        <description>• Changes in clinical laboratory results: Urinalysis - pH.</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.23 of 7)</title>
          <description>• Changes in clinical laboratory results: Urinalysis - pH.</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.220" spread="0.7511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (pH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.300" spread="0.7773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (pH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="0.8977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (6.24 of 7)</title>
        <description>• Changes in clinical laboratory results: Urinalysis - Specific Gravity.</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (6.24 of 7)</title>
          <description>• Changes in clinical laboratory results: Urinalysis - Specific Gravity.</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented are changes from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>Specific Gravity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Specific Gravity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.020" spread="0.0085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit (Specific Gravity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.022" spread="0.0060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Final Visit (Spec.Gravity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.0081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Outcome (7 of 7)</title>
        <description>• Physical examination findings including abnormal clinically significant findings</description>
        <time_frame>3 months (signed informed consent/assent to the final visit)</time_frame>
        <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented is a clinically significant change from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cambia®</title>
            <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome (7 of 7)</title>
          <description>• Physical examination findings including abnormal clinically significant findings</description>
          <population>The Safety population included all subjects who have received at least 1 dose of study drug.
The data presented is a clinically significant change from baseline to the final visit. Baseline is defined as the last measurement taken before first treatment with study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months (signed informed consent/assent to 30 days post Day 90 or last dose of study medication taken)</time_frame>
      <desc>The Safety population included all subjects who have received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cambia®</title>
          <description>Diclofenac Potassium for Oral Solution (NSAID), 50 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion Sickness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Depomed</organization>
      <phone>510-744-8000</phone>
      <email>clinicaltrials@depomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

